Exploring new cancer treatments using bystander T cells
Paving the way for bystander T cell immunotherapies
['FUNDING_CAREER'] · UNIVERSITY OF MINNESOTA · NIH-11034352
This study is exploring how certain immune cells, called bystander T cells, can be activated to help fight cancer, with the hope of creating new treatment options that work better for patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-11034352 on ClinicalTrials.gov |
What this research studies
This research investigates the potential of bystander T cells, which are often overlooked in cancer immunotherapy, to become effective in fighting tumors. The approach focuses on understanding how these T cells can be activated outside of tumors and how they can be utilized to enhance anti-cancer responses. By leveraging the unique properties of bystander T cells, the research aims to develop novel therapies that could overcome the limitations faced by traditional tumor-specific T cell therapies. Patients may benefit from new treatment options that harness their immune system more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with solid tumors who may not respond well to conventional T cell therapies.
Not a fit: Patients with cancers that are not solid tumors or those who have already responded well to existing T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative cancer therapies that improve patient outcomes by utilizing bystander T cells to combat tumors.
How similar studies have performed: While the concept of targeting bystander T cells is relatively novel, there is emerging interest in this area, suggesting potential for success based on preliminary findings in related research.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAURICE, NICHOLAS JOSEPH — UNIVERSITY OF MINNESOTA
- Study coordinator: MAURICE, NICHOLAS JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy